Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with... von Felip, E., Orlov, S., Park, K., Yu, C.-J., Tsai, C.-M., Nishio, M., Dols, M.C., McKeage, M., Su, W.-C., Mok, T.S.K., Scagliotti, G., Spigel, D.R., Passos, V.Q., Chen, V., Munarini, F., Shaw, A.

Volltext

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stag... von Tan, D.S.W., Kim, T.M., Solomon, B.J., Tan, W.L., Yu, C.-J., Geater, S., De Castro, G., Greystoke, A., Felip, E., Johnson, B.E., Deudon, S., Louveau, A.-L., Passos, V.Q., Cho, B.C.

Volltext

Safety and efficacy of pasireotide in dumping syndromeresults from a phase 2, multicentre study von Tack, J, Aberle, J, Arts, J, Laville, M, Oppert, J.M, Bender, G, Bhoyrul, S, McLaughlin, T, Yoshikawa, T, Vella, A, Zhou, J, Passos, V.Q, O'Connell, P, Van Beek, A.P

Volltext

Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3) von Felip, E., Nishio, M., Orlov, S., Park, K., Yu, C.-J., Tsai, C.-M., Cobo, M., McKeage, M., Su, W.-C., SK Mok, T., Scagliotti, G.V., Spigel, D., Passos, V.Q., Chen, Z., Shaw, A.T.

Volltext

Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8) von Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R.

Volltext

Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8) von Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R.

Volltext

445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously tr... von Zhang, L., Shi, Y., Tan, D.S.W., Hu, B., Xiaoqing, L., Cheng, Y., Zhou, J., An, T., Lu, Y., Zhu, B., Bai, C., Jappe, A., Passos, V.Q., Lau, Y.Y., Wang, Q., Wu, Y-L.

Volltext

445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK+) non-small cell lung cancer (NSCLC) previously t... von Zhang, L., Shi, Y., Tan, D.S.W., Hu, B., Xiaoqing, L., Cheng, Y., Zhou, J., An, T., Lu, Y., Zhu, B., Bai, C., Jappe, A., Passos, V.Q., Lau, Y.Y., Wang, Q., Wu, Y.-L.

Volltext

OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC von Cho, B.C., Obermannová, R., Bearz, A., Kim, D., Orlov, S., Borra, G., Kim, S., Postmus, P.E., Laurie, S., Park, K., Geater, S., Bettini, A.C., Osborne, K., Passos, V.Q., Chen, Z., Dziadziuszko, R.

Volltext